Method of treating a methionine-dependent cancer
AssigneeAgency for Science, Technology and Research
InventorsZhenxun Wang, Wai Leong Tam, Lian Yee Yip, Ying Swan Ho, Zhengwei Wu, Bing Lim
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.
Claims4
A method of treating cancer or reducing the risk of recurrence of cancer in a subject;
- the method comprising the steps of:
- a) detecting increased expression levels of methionine adenosyltransferase 2A (MAT2A), methylthioadenosine phosphorylase (MTAP) and cluster of differentiation (CD166) biomarkers in a cancer specimen obtained from the subject,
- b) identifying the subject as one who is suitable for treatment with a methionine-cycle inhibitor when the expression levels of the biomarkers in the cancer specimen are increased as compared to the expression levels of the biomarkers in a non-cancerous specimen;
- and
- c) administering a methionine cycle inhibitor to the subject when the subject is identified as one who is suitable for treatment with the methionine-cycle inhibitor, so as to treat cancer or reduce the risk of recurrence of cancer in the subject,
- wherein the methionine-cycle inhibitor is a MAT2A inhibitor, D9, methotrexate or anti-folate.
The method of 1, wherein the subject is one who has previously had an anti-cancer therapy.
The method of 1, wherein the cancer is a methionine-dependent cancer.
A method of treating cancer or reducing the risk of recurrence of cancer in a subject;
- the method comprising the steps of:
- a) selecting a subject having increased expression levels of MAT2A, MTAP and CD166 biomarkers in a cancer specimen obtained from the subject,
- b) identifying the subject as one who is suitable for treatment with a methionine-cycle inhibitor when the expression levels of the biomarkers in the cancer specimen are increased as compared to the expression levels of the biomarkers in a non-cancerous specimen;
- and
- c) administering a methionine cycle inhibitor to the subject when the subject is identified as one who is suitable for treatment with the methionine-cycle inhibitor, so as to treat cancer or reduce the risk of recurrence of cancer in the subject,
- wherein the methionine-cycle inhibitor is a MAT2A inhibitor, D9, methotrexate or anti-folate.
Dependencies are inferred from the claim text.